VitalHub Corp. (TSX:VHI)

VitalHub has moved into focus this September after another quarter of rapid, acquisition-led growth from a company that remains small relative to the healthcare-technology market it serves. The Toronto-based firm provides software to hospitals, health systems and community and social-services organizations, and its second-quarter 2026 results, released on 6 August 2026, showed strong Revenue and recurring-revenue momentum.

Second-quarter results

VitalHub reported total revenue of $31.7 million for the quarter, up 33% year over year. Term-license, maintenance and support revenue was $24.5 million, or about 77% of the total, underlining the recurring nature of the business. Annual Recurring Revenue reached $101.5 million as at 30 June 2026, up 28% from a year earlier, with organic ARR growth of 10%.

Profitability also improved. Adjusted EBITDA was $8.2 million, representing 26% of revenue and up 29% year over year, while Net Income rose 10% to $1.95 million. The company ended the quarter with $136.5 million in cash and short-term investments, giving it substantial capacity to keep funding acquisitions.

Acquisitions remain central

VitalHub's model combines organic growth with a steady cadence of acquisitions. Shortly after quarter-end, on 10 July 2026, the company acquired Buddy Healthcare for approximately $13.4 million, adding around $4.5 million to pro forma ARR and lifting pro forma annual recurring revenue to roughly $106.0 million. The deal is consistent with a strategy of buying complementary healthcare-software businesses and integrating them onto the group's platform.

Why it matters

The mix of strong reported growth, high recurring revenue, improving adjusted EBITDA and a large cash balance is what draws investors to VitalHub. Recurring revenue at more than three-quarters of the total provides visibility, while the cash position of $136.5 million and access to Capital support continued deal-making without immediate reliance on heavily dilutive Equity raises. At the same time, the 10% organic ARR growth rate is a reminder that a meaningful share of headline growth comes from acquisitions rather than the existing base.

Sector context

Health-system software spending is supported by long-term pressures to digitise patient flow, reduce wait times and improve operational efficiency across hospitals and community care. VitalHub sells into the United Kingdom, Canada, Australia and other markets, exposing it to public-sector procurement cycles and currency movements. The fragmented nature of healthcare software creates a long runway of potential Acquisition targets, but also brings integration complexity as multiple products are folded into the group.

What to watch next

Key items include the pace of organic ARR growth, integration and contribution from Buddy Healthcare and prior acquisitions, adjusted EBITDA margins as the company scales, and how quickly the sizeable cash balance is deployed into new deals. New contract wins in core markets and any large tender awards would also be important signals.

Key risks

Risks include reliance on acquisitions to sustain headline growth, integration and execution risk, exposure to public-sector budget and procurement cycles, and currency effects given international revenue. A slower deal pace or weaker organic growth could temper the story, and small-cap technology shares can be especially volatile.

Conclusion

VitalHub's second quarter combined 33% revenue growth, 28% ARR growth, improved profitability and a strong balance sheet, with a further acquisition completed just after the period. The reliance on deals and modest organic growth rate are worth weighing, but recurring revenue, cash firepower and a clear acquisition strategy explain why the company is on watchlists. For investors, the key question is whether organic momentum can build alongside continued acquisitions through the remainder of 2026.